NMPA Accepts Everest LEROCHOL PCSK9 BLA
Everest LEROCHOL NMPA BLA acceptance China moves the once-monthly PCSK9 inhibitor into formal review for adult hypercholesterolemia including HeFH. Everest Medicines said on June 26, 2026 that the biologics filing is now under CDE evaluation after China and global Phase 3 support.
Contents9 sections
Key Takeaways
- NMPA accepted Everest's BLA for LEROCHOL (lerodalcibep) in adult hypercholesterolemia / HeFH.
- Recommended regimen cited: 300 mg subcutaneous once monthly; room-temperature stability up to 3 months.
- China Phase 3 placebo-adjusted LDL-C drops near 66–67% at weeks 10–12 (company).
- FDA approval already secured (December 2025); EMA review ongoing; China approval eyed for 2027.
LEROCHOL China BLA at a glance
| Field | Detail |
|---|---|
| Product | LEROCHOL (lerodalcibep / lerodalcibep-liga) |
| Class | Third-generation PCSK9 inhibitor (Adnectin–HSA fusion) |
| Applicant (China) | Everest Medicines |
| Originator context | LIB Therapeutics (FDA approval holder) |
| Regulator action | NMPA BLA acceptance (June 26, 2026) |
| Dose cited | 300 mg SC once monthly |
| U.S. status | FDA approved December 12, 2025 |
What did Everest announce?
Everest said NMPA accepted a BLA seeking approval of LEROCHOL as an adjunct to diet and exercise for LDL-C lowering in adults with hypercholesterolemia, including HeFH. The company framed the product as a convenience-differentiated PCSK9 option with monthly dosing and extended room-temperature stability for home use and travel.
Source: Everest Medicines' June 26 PR Newswire BLA-acceptance release.
What efficacy package was cited?
- China Phase 3: placebo-adjusted LDL-C −65.9% at week 12; −67.0% mean of weeks 10 and 12
- >95% of China LEROCHOL participants meeting dual Chinese guideline LDL-C targets (company)
- Global trials: sustained ≥60% LDL-C reductions in high/very-high CVD risk and ~59% in HeFH
U.S. labeling context for the FDA-approved product can be checked via FDA drugs resources. Lipid-endpoint trials are indexed on ClinicalTrials.gov.
Why does China access matter?
Everest cited roughly 400 million people with dyslipidemia in China and only about 14% on lipid-lowering therapy, underscoring under-treatment versus guideline LDL-C goals. A monthly small-volume injectable with room-temperature flexibility could help long-term adherence if priced and reimbursed for high-risk cohorts, including HeFH.
BLA acceptance starts the clock on CDE questions around immunogenicity of the Adnectin construct, manufacturing scale-up, and how China labeling should map to U.S. FDA text. Competitive pressure from monoclonal PCSK9 antibodies and oral options will shape uptake even after approval.
What remains uncertain?
NMPA review duration, NRDL timing, and final China Product Information were not disclosed. Company 2027 approval language is aspirational. Head-to-head data versus established PCSK9 mAbs were not the basis of the acceptance notice.
Related NovaPharma coverage
- NMPA Approves Ciprocopan for PNH in China
- NMPA Accepts Toripalimab Perioperative NSCLC sNDA
- Takeda TAK-003 Wins India Dengue Vaccine Nod
Frequently Asked Questions
What did NMPA accept for LEROCHOL?
On June 26, 2026, Everest Medicines said China's National Medical Products Administration accepted a Biologics License Application for LEROCHOL (lerodalcibep) for subcutaneous use as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
What efficacy did Everest cite from China Phase 3?
Everest said a China Phase 3 trial showed mean placebo-adjusted LDL-C reductions of 65.9% at week 12 and 67.0% for the mean of weeks 10 and 12, with more than 95% of LEROCHOL participants achieving dual Chinese lipid-guideline LDL-C targets. Global trials were cited for sustained reductions of about 60% in high-risk and HeFH populations.
Is LEROCHOL already approved elsewhere?
Yes. Everest said the FDA approved LEROCHOL on December 12, 2025, and that an EMA marketing application remains under review. China approval timing was described as potentially 2027 if the NMPA review succeeds.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for LEROCHOL.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
